122 related articles for article (PubMed ID: 10936741)
1. Drug concentration effect relationship of estradiol from two matrix transdermal delivery systems: Menorest and Climara.
Andersson TL; Stehle B; Davidsson B; Höglund P
Maturitas; 2000 Jun; 35(3):245-52. PubMed ID: 10936741
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of estradiol from two matrix transdermal delivery systems: Menorest and Climara.
Andersson TL; Stehle B; Davidsson B; Höglund P
Maturitas; 2000 Jan; 34(1):57-64. PubMed ID: 10687883
[TBL] [Abstract][Full Text] [Related]
3. Comparative bioequivalence studies with Estradot and Menorest transdermal systems.
Hossain M; Quebe-Fehling E; Sergejew T; Schmidt G; Skerjanec A; Cohen A; Krinsky L; Ibarra de Palacios P
Maturitas; 2003 Nov; 46(3):187-98. PubMed ID: 14585521
[TBL] [Abstract][Full Text] [Related]
4. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
Rohr UD; Nauert C; Stehle B
Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
[TBL] [Abstract][Full Text] [Related]
5. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara.
Buch A; Shen L; Kelly S; Sahota R; Brezovic C; Bixler C; Powell J
Menopause; 1998; 5(2):107-12. PubMed ID: 9689205
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
[TBL] [Abstract][Full Text] [Related]
7. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50.
Reginster JY; Albert A; Deroisy R; Colette J; Vrijens B; Blacker C; Brion N; Caulin F; Mayolle C; Regnard A; Scholler R; Franchimont P
Maturitas; 1997 Jun; 27(2):179-86. PubMed ID: 9255753
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of bioequivalence of two 7-day 17beta-estradiol transdermal delivery systems by anatomical site.
Harrison LL; Harari D
J Clin Pharmacol; 2002 Oct; 42(10):1134-41. PubMed ID: 12362928
[TBL] [Abstract][Full Text] [Related]
9. New trends in transdermal technologies: development of the skin patch, Menorest.
Marty JP
Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S17-20. PubMed ID: 8666122
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy.
Gordon SF
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 2):998-1004. PubMed ID: 7573298
[TBL] [Abstract][Full Text] [Related]
11. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch.
Järvinen A; Bäckström A; Elfström C; Viitanen A
Maturitas; 2001 Apr; 38(2):189-96. PubMed ID: 11306208
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir System.
Le Roux Y; Borg ML; Sibille M; Thebault J; Renoux A; Douin MJ; Djebbar F; Dain MP
Clin Drug Investig; 1995 Sep; 10(3):172-8. PubMed ID: 27519201
[TBL] [Abstract][Full Text] [Related]
13. The effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara).
Taggart W; Dandekar K; Ellman H; Notelovitz M
Menopause; 2000; 7(5):364-9. PubMed ID: 10993035
[TBL] [Abstract][Full Text] [Related]
14. Menorest: technical development and pharmacokinetic profile.
Marty JP
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S29-33. PubMed ID: 8732471
[TBL] [Abstract][Full Text] [Related]
15. [Effect of a 17 beta estradiol gel preparation on hormone levels in menopausal women].
Araya V; Contreras P; Aguirre C; Foradori A
Rev Med Chil; 1995 Sep; 123(9):1116-21. PubMed ID: 8728735
[TBL] [Abstract][Full Text] [Related]
16. Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women.
Baracat E; Haidar M; Castelo A; Tufik S; de Lima GR; Vieira JG; Peloso U; Casoy J
Maturitas; 1996 Apr; 23(3):285-91. PubMed ID: 8794422
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study.
Studd JW; McCarthy K; Zamblera D; Burger HG; Silberberg S; Wren B; Dain MP; Le Lann L; Vandepol C
Maturitas; 1995 Sep; 22(2):105-14. PubMed ID: 8538478
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with an established transdermal membrane system (Estraderm TTS).
Erianne JA; Winter L
Maturitas; 1997 Mar; 26(2):95-101. PubMed ID: 9089558
[TBL] [Abstract][Full Text] [Related]
19. [Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system].
Schmolling J; Kusche J; van der Ven H; Schander K
Zentralbl Gynakol; 1998; 120(3):121-5. PubMed ID: 9556902
[TBL] [Abstract][Full Text] [Related]
20. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch.
Setnikar I; Rovati LC; Santoro A; Guillaume M; Mignot A; Renoux A; Gualano V
Arzneimittelforschung; 1999 Aug; 49(8):708-15. PubMed ID: 10483519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
